Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review.

Rev Cardiovasc Med · 2026 · PMC13227382 · PMID 42238623

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Despite the lack of statistical significance, riociguat replacement therapy showed a numerical trend toward greater efficacy in preventing clinical worsening than selexipag add-on therapy.

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.